MarketWatch Moderna’s stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.
The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.